

10/714,078
Search W/COOK
9/5/07

d his

(FILE 'HOME' ENTERED AT 12:19:15 ON 05 SEP 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 12:19:53 ON 05 SEP 2007

L1 488 S HEMODIALYSIS AND (VENTRICULAR FUNCTION)
L2 82 S L1 AND STROKE
L3 61 DUPLICATE REMOVE L2 (21 DUPLICATES REMOVED)
L4 42 S L3 AND PD<2001
L5 1 S L4 AND BNP
L6 12784 S STROKE AND (VENTRICULAR FUNCTION)
L7 9499 S L6 AND PD<2001
L8 9457 S L7 NOT L4
L9 15 S L8 AND BNP

=>

ANSWER 25 OF 42 MEDLINE on STN

AN 92343603 MEDLINE

DN PubMed ID: 1386184

TI Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin.

AU Goldberg N; Lundin A P; Delano B; Friedman E A; Stein R A

CS Department of Medicine, SUNY-Health Science Center, Brooklyn 11203.

SO American heart journal, (1992 Aug) Vol. 124, No. 2, pp. 424-7.
Journal code: 0370465. ISSN: 0002-8703.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199208

ED Entered STN: 11 Sep 1992
Last Updated on STN: 3 Mar 2000
Entered Medline: 24 Aug 1992

AB Left ventricular size and function were evaluated in 15 anemic chronic hemodialysis patients before and after the administration of recombinant human erythropoietin (rHuEPO). All patients were studied with two-dimensional and M-mode echocardiographic examinations before the initiation of rHuEPO (T1) and at 28 +/- 7 weeks of rHuEPO therapy (T2). The two-dimensional targeted M-mode echocardiographic measurements obtained were: end-diastolic dimension (EDD); end-systolic dimension (ESD); stroke dimension (SD); dimensional shortening (SD/EDD); systolic posterior wall thickness (PWs); diastolic posterior and interventricular septal thickness; end-systolic wall stress (ESWS); and left ventricular mass. Mean hematocrit in these patients increased almost 50%. The EDD decreased from a mean value (+/- SEM) of 6.41 +/- 0.33 to 4.93 +/- 0.21 cm (p less than 0.05). ESD decreased from a mean value of 4.16 +/- 1.2 to 2.77 +/- 0.06 cm (p less than 0.05). The calculated mean SD decreased slightly but not significantly from 2.21 +/- 0.69 to 2.19 +/- 0.60 cm. The calculated SD/EDD increased from a mean 0.35 +/- 0.09 to 0.44 +/- 0.07 (p less than 0.05). ESWS fell from 59.2 +/- 12.2 to 37.6 +/- 9.3 gm/cm2 (p less than 0.01), and left ventricular mass fell (p less than 0.05) from 347 +/- 15.2 to 227 +/- 59 gm. There was no significant difference in resting heart rate or systolic blood pressure between T1 and T2. The increase in dimension shortening reflects afterload reduction, as indicated by the fall in end-systolic wall stress. (ABSTRACT TRUNCATED AT 250 WORDS)

CT Check Tags: Female; Male
Adult
*Anemia: DT, drug therapy
Anemia: ET, etiology
Cardiomegaly: PP, physiopathology
*Cardiomegaly: US, ultrasonography
Echocardiography
*Erythropoietin: TU, therapeutic use
Humans
*Kidney Failure, Chronic: CO, complications
Kidney Failure, Chronic: TH, therapy
Recombinant Proteins: TU, therapeutic use
Renal Dialysis
*Ventricular Function, Left: DE, drug effects

RN 11096-26-7 (Erythropoietin)

CN 0 (Recombinant Proteins)

ANSWER 25 OF 42 MEDLINE on STN

AN 92343603 MEDLINE

DN PubMed ID: 1386184

TI Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin.

AU Goldberg N; Lundin A P; Delano B; Friedman E A; Stein R A

CS Department of Medicine, SUNY-Health Science Center, Brooklyn 11203.

SO American heart journal, (1992 Aug) Vol. 124, No. 2, pp. 424-7.
Journal code: 0370465. ISSN: 0002-8703.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199208

ED Entered STN: 11 Sep 1992
Last Updated on STN: 3 Mar 2000
Entered Medline: 24 Aug 1992

AB Left ventricular size and function were evaluated in 15 anemic chronic hemodialysis patients before and after the administration of recombinant human erythropoietin (rHuEPO). All patients were studied with two-dimensional and M-mode echocardiographic examinations before the initiation of rHuEPO (T1) and at 28 +/- 7 weeks of rHuEPO therapy (T2). The two-dimensional targeted M-mode echocardiographic measurements obtained were: end-diastolic dimension (EDD); end-systolic dimension (ESD); stroke dimension (SD); dimensional shortening (SD/EDD); systolic posterior wall thickness (PWs); diastolic posterior and interventricular septal thickness; end-systolic wall stress (ESWS); and left ventricular mass. Mean hematocrit in these patients increased almost 50%. The EDD decreased from a mean value (+/- SEM) of 6.41 +/- 0.33 to 4.93 +/- 0.21 cm (p less than 0.05). ESD decreased from a mean value of 4.16 +/- 1.2 to 2.77 +/- 0.06 cm (p less than 0.05). The calculated mean SD decreased slightly but not significantly from 2.21 +/- 0.69 to 2.19 +/- 0.60 cm. The calculated SD/EDD increased from a mean 0.35 +/- 0.09 to 0.44 +/- 0.07 (p less than 0.05). ESWS fell from 59.2 +/- 12.2 to 37.6 +/- 9.3 gm/cm2 (p less than 0.01), and left ventricular mass fell (p less than 0.05) from 347 +/- 15.2 to 227 +/- 59 gm. There was no significant difference in resting heart rate or systolic blood pressure between T1 and T2. The increase in dimension shortening reflects afterload reduction, as indicated by the fall in end-systolic wall stress. (ABSTRACT TRUNCATED AT 250 WORDS)

CT Check Tags: Female; Male
Adult
*Anemia: DT, drug therapy
Anemia: ET, etiology
Cardiomegaly: PP, physiopathology
*Cardiomegaly: US, ultrasonography
Echocardiography
*Erythropoietin: TU, therapeutic use
Humans
*Kidney Failure, Chronic: CO, complications
Kidney Failure, Chronic: TH, therapy
Recombinant Proteins: TU, therapeutic use
Renal Dialysis
*Ventricular Function, Left: DE, drug effects

RN 11096-26-7 (Erythropoietin)

CN 0 (Recombinant Proteins)

ANSWER 6 OF 15 MEDLINE on STN

AN 1998166212 MEDLINE

DN PubMed ID: 9505313

TI Perioperative changes in plasma brain natriuretic peptide concentrations in patients undergoing cardiac surgery.

AU Morimoto K; Mori T; Ishiguro S; Matsuda N; Hara Y; Kuroda H

CS Second Department of Surgery, Tottori University Faculty of Medicine, Japan.

SO Surgery today, (1998) Vol. 28, No. 1, pp. 23-9.
Journal code: 9204360. ISSN: 0941-1291.

CY Japan

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199805

ED Entered STN: 20 May 1998
Last Updated on STN: 29 Jan 1999
Entered Medline: 8 May 1998

AB The plasma concentrations of brain natriuretic peptide (BNP), a cardiac hormone, were measured in 30 consecutive adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) during the perioperative period. BNP concentrations remained unchanged until 6 h after the cessation of bypass, and were elevated 12, 24, and 48 h post-bypass ($P < 0.0001$ versus baseline). They had returned to the baseline values when measured 3 weeks postoperatively. The preoperative plasma BNP concentration correlated significantly with the left ventricular ejection fraction ($r = -0.895$). The peak plasma BNP concentration 24 h after bypass correlated with the cardiac index ($r = -0.64$), stroke volume index ($r = -0.62$), injection rate of dopamine hydrochloride ($r = 0.65$), and aortic crossclamp time ($r = 0.57$). There was also a significant correlation between the preoperative BNP concentration and the plasma BNP concentration 24 h post-CPB. These findings led us to conclude that the plasma concentrations of BNP become markedly and acutely elevated after cardiac surgery with CPB, and reflect the state of left ventricular function. Moreover, the severity of acute heart failure after cardiac surgery can be predicted by the preoperative plasma BNP concentration.

CT Check Tags: Female; Male
*Cardiac Surgical Procedures
Cardiopulmonary Bypass
Hemodynamic Processes: PH, physiology
Humans
Intraoperative Period
Middle Aged
Natriuretic Peptide, Brain
*Nerve Tissue Proteins: BL, blood
Postoperative Period
Prospective Studies
Time Factors
Ventricular Function, Left: PH, physiology

RN 114471-18-0 (Natriuretic Peptide, Brain)

CN 0 (Nerve Tissue Proteins)

ANSWER 6 OF 15 MEDLINE on STN

AN 1998166212 MEDLINE
DN PubMed ID: 9505313
TI Perioperative changes in plasma brain natriuretic peptide concentrations in patients undergoing cardiac surgery.
AU Morimoto K; Mori T; Ishiguro S; Matsuda N; Hara Y; Kuroda H
CS Second Department of Surgery, Tottori University Faculty of Medicine, Japan.
SO Surgery today, (1998) Vol. 28, No. 1, pp. 23-9.
Journal code: 9204360. ISSN: 0941-1291.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199805
ED Entered STN: 20 May 1998
Last Updated on STN: 29 Jan 1999
Entered Medline: 8 May 1998
AB The plasma concentrations of brain natriuretic peptide (BNP), a cardiac hormone, were measured in 30 consecutive adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) during the perioperative period. BNP concentrations remained unchanged until 6 h after the cessation of bypass, and were elevated 12, 24, and 48 h post-bypass ($P < 0.0001$ versus baseline). They had returned to the baseline values when measured 3 weeks postoperatively. The preoperative plasma BNP concentration correlated significantly with the left ventricular ejection fraction ($r = -0.895$). The peak plasma BNP concentration 24 h after bypass correlated with the cardiac index ($r = -0.64$), stroke volume index ($r = -0.62$), injection rate of dopamine hydrochloride ($r = 0.65$), and aortic crossclamp time ($r = 0.57$). There was also a significant correlation between the preoperative BNP concentration and the plasma BNP concentration 24 h post-CPB. These findings led us to conclude that the plasma concentrations of BNP become markedly and acutely elevated after cardiac surgery with CPB, and reflect the state of left ventricular function. Moreover, the severity of acute heart failure after cardiac surgery can be predicted by the preoperative plasma BNP concentration.
CT Check Tags: Female; Male
*Cardiac Surgical Procedures
Cardiopulmonary Bypass
Hemodynamic Processes: PH, physiology
Humans
Intraoperative Period
Middle Aged
Natriuretic Peptide, Brain
*Nerve Tissue Proteins: BL, blood
Postoperative Period
Prospective Studies
Time Factors
Ventricular Function, Left: PH, physiology
RN 114471-18-0 (Natriuretic Peptide, Brain)
CN 0 (Nerve Tissue Proteins)

d his

(FILE 'HOME' ENTERED AT 12:19:15 ON 05 SEP 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 12:19:53 ON 05 SEP 2007

L1 488 S HEMODIALYSIS AND (VENTRICULAR FUNCTION)
L2 82 S L1 AND STROKE
L3 61 DUPLICATE REMOVE L2 (21 DUPLICATES REMOVED)
L4 42 S L3 AND PD<2001
L5 1 S L4 AND BNP
L6 12784 S STROKE AND (VENTRICULAR FUNCTION)
L7 9499 S L6 AND PD<2001
L8 9457 S L7 NOT L4
L9 15 S L8 AND BNP

=>